Michael Curtis, incoming eGenesis CEO

Ex­clu­sive: En route to first xeno­trans­plan­ta­tion tri­al, eGe­n­e­sis taps new CEO weeks af­ter CMO hire

When Michael Cur­tis joined xeno­trans­plan­ta­tion start­up eGe­n­e­sis as pres­i­dent of R&D in late-2020, he knew he’d one day be­come CEO.

He and Paul Sekhri, the out­go­ing CEO who will re­main on the board of the Church lab spin­out and serve as se­nior ad­vi­sor, have spent the past 18 months map­ping out that tran­si­tion. He climbs the lad­der just two weeks af­ter eGe­n­e­sis hired for­mer trans­plant sur­geon and two-decade clin­i­cal de­vel­op­ment leader Eliez­er Katz as med­ical chief.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA